AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00552227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: oral 32 mg daily
Study NCT00552227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04103411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24h-Ambulatory Blood Pressure
Description: Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
Study NCT04103411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24h-Ambulatory Blood Pressure
Description: Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
Study NCT00730288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric dengue serotype (1, 2, 3, 4)
Description: 0.5 mL, Subcutaneous, 1 dose
Study NCT00730288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric dengue serotype (1, 2, 3, 4)
Description: 0.5mL, Subcutaneous, 1 dose
Study NCT02373735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: crystalloid
Description: Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
Study NCT02373735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crystalloid
Description: Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
Study NCT02373735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colloid
Description: Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is > 20%
Study NCT02373735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: colloid
Description: Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is > 20%
Study NCT02373735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mannitol
Description: Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is \< 10%
Study NCT02373735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lasix
Description: Group B (SVV 10-20%): infuse lasix 5 mg if SVV is \< 10%
Study NCT00080288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Description: Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
Study NCT00080288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily
Study NCT01215682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 2000 IU/day of vitamin D3 as a once-daily dose
Study NCT02953626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Matters Online Postpartum Support Group
Description: Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared.
Study NCT01418378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma CR150
Description: Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
Study NCT01418378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma CR
Description: Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
Study NCT00788671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00788671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine System
Description: Undergo placement of a levonorgestrel-releasing intrauterine system
Study NCT01215682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sweetened water
Study NCT01658787 — intervention group
Intervention type: DEVICE
Intervention: Endovascular aortic repair
Description: Treatment with Gore Endovascular Aortic Products.
Study NCT00388414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30-60mg of duloxetine daily
Study NCT00388414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill once daily
Study NCT01156701 — intervention group
Intervention type: DRUG
Intervention: Receiving a prescription of Relenza for prophylaxis
Description: Receiving a prescription of Relenza for prophylaxis
Study NCT01156701 — intervention group
Intervention type: OTHER
Intervention: No prophylaxis with Relenza
Description: No prophylaxis with Relenza
Study NCT00778466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride 1000 mg tablets
Study NCT00778466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride 1000 mg tablets
Study NCT02082054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSE 120 mg, CM 8 mg, Atr 0.36 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side
Study NCT02082054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSE 120 mg, CM 8 mg, Atr 0.24 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side
Study NCT02082054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSE 120 mg, CM 8 mg, Atr 0.12 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side
Study NCT02082054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PSE 120 mg, CM 8 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
Study NCT02082054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.24 mg
Description: Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side
Study NCT02541929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Study NCT02541929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Docosahexaenoic acid
Study NCT01220557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIMAS
Description: PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
Study NCT01220557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTTP
Description: The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
Study NCT02854540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel electrode-based iontophoresis
Description: Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
Study NCT03634774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHOICE+ Training Program
Description: CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
Study NCT03634774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CHOICE+ Training Program
Description: CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
Study NCT02866253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
Study NCT04989270 — intervention group
Intervention type: PROCEDURE
Intervention: General Anesthesia
Description: General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis
Study NCT04989270 — intervention group
Intervention type: PROCEDURE
Intervention: Regional Anesthesia
Description: Spinal Anesthesia, Epidural Anesthesia
Study NCT03906370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic criteria for MS
Description: The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
Study NCT04895267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-field thoracic magnetic stimulation (LF-ThMS)
Description: A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
Study NCT04895267 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-field thoracic magnetic stimulation (LF-ThMS)
Description: A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
Study NCT01437592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
Study NCT02449538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus 10 mg qd daily one cycle is 28days.
Study NCT03176693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxybenzamine
Description: Non-selective alpha blocker
Study NCT03176693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Selective alpha blocker
Study NCT04266028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101
Description: DM-101 administered by subcutaneous (SC) injection
Study NCT04266028 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match DM-101
Description: Placebo to match DM-101 administered by SC injection
Study NCT00650546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5 mcg twice a day titrated to 10 mcg twice a day
Study NCT02870790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: one pill daily
Study NCT01244152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive diabetes self-management education
Description: 18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
Study NCT01244152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard diabetes education
Description: 2 3-hour diabetes education classes taught by a health educator at a local clinic
Study NCT03301051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine
Description: Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
Study NCT03301051 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of a Placebo
Study NCT02042235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-implemented intervention
Description: In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
Study NCT03969238 — intervention group
Intervention type: BEHAVIORAL
Intervention: Helpline
Description: This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
Study NCT01191489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Conditioned Oxygen Therapy in High Risk Patients
Description: OptiFlow system (R) with nasal cannula.
Study NCT01191489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive mechanical ventilation
Description: Bilevel pressure support through a facial mask
Study NCT01191489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
Study NCT03787667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT or MRI based Radiomics
Description: Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
Study NCT01813240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Study NCT01813240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03219983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
Study NCT03219983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivacaine
Description: A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
Study NCT00497653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCI
Description: D-chiro-inositol 1200mg twicely daily for 6 weeks
Study NCT00497653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, twice daily for 6 weeks
Study NCT05226208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual analogue scale (VAS)
Description: In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
Study NCT05226208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: General anxiety scale (GAD-2) and survey
Description: In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
Study NCT03843918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAE001
Description: LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
Study NCT06559488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection [Avastin]
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
Study NCT06559488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars Plana Vitrectomy
Description: routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
Study NCT02450994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02450994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02568787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice bran arabinoxylan compound (RBAC)
Description: Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
Study NCT02568787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
Study NCT01344460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: a single bolus injection of approx. 0.1mmol/kg
Study NCT00788671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03380143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Landscape Intervention
Description: Community and organization systems intervention targeting youth population physical activity
Study NCT03380143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Community development intervention
Study NCT01001715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475/SAR164877
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Study NCT01001715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for REGN475/SAR164877)
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Study NCT04449640 — intervention group
Intervention type: PROCEDURE
Intervention: Hysteroscopic septum resection.
Description: Resection of a uterine septum by hysteroscopic surgery.
Study NCT01270373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAC x 3 followed by Docetaxel x 3
Description: 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
Study NCT01270373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel x 3 followed by FAC x 3
Description: Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
Study NCT01249391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting
Description: Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
Study NCT04312919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Activity Intervention
Description: Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
Study NCT04312919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Activity Intervention
Description: Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
Study NCT03856671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin,metronidazole
Description: Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
Study NCT03543033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
Study NCT00947765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Description: Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
Study NCT00947765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local corticosteroid injection
Description: Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
Study NCT03360526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.